What's the Lowest Dose of Metformin You Can Take?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 10 sources cited

Key Takeaways

• The smallest commercially available metformin tablet in the U.S. is 500 mg (immediate-release). Extended-release tablets come in 500, 750, and 1,000 mg.
• A 500 mg IR tablet can be split in half to 250 mg, which is a common true minimum starting dose for sensitive patients.
• 500 mg/day produces about 0.6% A1C reduction in clinical trials, which is meaningful but smaller than the 1.4% to 2.0% reduction at higher doses.
• Low-dose metformin (250 to 500 mg) is sometimes used for PCOS, prediabetes, and aging-related metabolic concerns at the lowest tolerated dose.
• ER tablets should not be split, since splitting destroys the slow-release coating.

Direct answer (40-60 words, snippet-optimized)

The lowest commercially available metformin dose is a 500 mg immediate-release tablet. With pill splitting, 250 mg is achievable. The label-recommended starting dose is 500 mg once daily with the evening meal. Doses below 500 mg/day rarely produce meaningful glycemic improvement but may be tolerable starting points for sensitive patients.

Table of contents

1. The 30-second answer
2. The smallest tablet sold
3. Can you split a 500 mg tablet?
4. Is 250 mg of metformin a real dose?
5. What 500 mg/day actually does
6. Low-dose metformin for prediabetes and PCOS
7. Low-dose metformin for longevity (off-label)
8. Comparing low-dose to maximum-dose
9. When to step up from low dose
10. Side effects at low doses
11. FAQ
12. Sources
13. Footer disclaimers

The smallest tablet sold

In the United States, metformin is sold in the following tablet strengths:

Formulation	Strengths	Notes
Immediate-release (IR)	500 mg, 850 mg, 1,000 mg	Most common; 500 mg is the smallest
Extended-release (ER, brand Glucophage XR and generics)	500 mg, 750 mg, 1,000 mg	Slow-release coating; do not split or crush
Liquid (Riomet)	500 mg per 5 mL	Useful for pediatric or dose-sensitive patients
Combination products (with sitagliptin, dapagliflozin, etc.)	Variable	Not relevant for low-dose monotherapy

The 500 mg IR tablet is the smallest single-strength solid form available. Riomet liquid lets you measure smaller doses (down to about 100 mg in 1 mL increments), but it's much less commonly prescribed.

There's no FDA-approved 250 mg metformin tablet sold commercially in the U.S. Some compounding pharmacies make 250 mg capsules on prescription, but these aren't widely available.

Can you split a 500 mg tablet?

For immediate-release metformin, yes. A 500 mg IR tablet can be split with a pill cutter to produce two 250 mg pieces. The tablets aren't scored at the factory in most generic versions, so the halves may not be perfectly equal, but the variation is clinically negligible at this dose.

For extended-release metformin, no. The ER coating regulates the slow absorption. Splitting an ER tablet breaks the coating and the medication releases too quickly, potentially causing GI side effects and changing the pharmacokinetic profile in unpredictable ways.

If you need a 250 mg dose and prefer ER, the practical option is 500 mg ER once daily, accepting the slightly higher dose, or switching to 250 mg IR (split tablet) twice daily, which approximates the same total daily exposure.

A common starting protocol for very sensitive patients:

• Week 1: 250 mg (half of a 500 mg IR tablet) once daily with dinner
• Week 2: 250 mg twice daily (with breakfast and dinner)
• Week 3: 500 mg in the morning, 250 mg with dinner
• Week 4+: 500 mg twice daily, then up as tolerated

This slow start dramatically reduces the GI side effects that cause many patients to quit metformin in the first few weeks.

Is 250 mg of metformin a real dose?

Pharmacologically, yes. 250 mg produces measurable plasma metformin levels and meaningful effects on hepatic glucose output and insulin sensitivity, though smaller than the effects at 500 mg and above.

Clinically, 250 mg/day is below the dose-response threshold where most diabetes guidelines see metformin as therapeutically useful for glycemic control. The DeFronzo trials (NEJM 1995) didn't test doses below 500 mg in their dose-finding work, so the formal A1C reduction at 250 mg isn't well characterized in published data.

For diabetes treatment, 250 mg/day is mostly used as a brief starter dose during titration. Patients who can't tolerate 500 mg/day after several weeks of trying are typically switched to a different medication rather than maintained at 250 mg long-term.

For non-diabetes uses (PCOS, prediabetes, longevity protocols), 250 to 500 mg/day is sometimes used as a maintenance dose, with the rationale being that the metabolic effects of metformin extend beyond glucose control and may be partially captured at lower doses.

What 500 mg/day actually does

500 mg/day metformin (the lowest commercial single-tablet dose) produces measurable but modest effects in trials.

In DeFronzo et al. (NEJM 1995), 500 mg/day reduced A1C by approximately 0.6 percentage points compared to placebo over 14 weeks, in patients with type 2 diabetes. This is a real effect, but it's less than half of what 1,500 to 2,000 mg/day produces.

For weight, 500 mg/day produces a small effect, on the order of 1 to 2 kg over 6 to 12 months in non-diabetic patients, compared to about 2 to 3 kg at 1,500 mg/day. The Diabetes Prevention Program (NEJM 2002) used 1,700 mg/day for prediabetes, which produced 31% reduction in progression to type 2 diabetes versus placebo. No similar large trial has tested 500 mg/day for prediabetes.

For PCOS, several smaller trials have used 500 to 1,000 mg/day with measurable effects on ovulation, insulin sensitivity, and androgen levels (Lord et al., Cochrane Database 2003). The effect appears to be partial at 500 mg and more pronounced at 1,500 to 2,000 mg, but tolerability favors lower doses for adherence.

A practical estimate: 500 mg/day metformin produces about 30 to 40% of the effect of maximum-dose metformin on most outcomes, with about 25 to 35% of the GI side effects. For many patients, that's a reasonable trade-off.

Low-dose metformin for prediabetes and PCOS

Two non-diabetes uses of low-dose metformin are common:

Prediabetes. The Diabetes Prevention Program established that 1,700 mg/day metformin reduces progression to type 2 diabetes by 31% over 3 years. Lower doses haven't been formally tested in DPP-scale trials. Some clinicians prescribe 500 to 1,000 mg/day for prediabetes, especially in patients who don't tolerate higher doses or who have only modest A1C elevations (5.7 to 6.2%). The American Diabetes Association recommends metformin consideration for prediabetic patients with BMI ≥35 or age <60 with strong family history.

PCOS (polycystic ovary syndrome). Metformin improves insulin sensitivity in PCOS, which can normalize ovulation and reduce androgen-related symptoms. Most PCOS protocols use 1,500 to 2,000 mg/day, but some patients respond meaningfully to 500 to 1,000 mg/day. The 2018 international PCOS guideline from the European Society of Human Reproduction and Embryology suggests starting at 500 mg/day and titrating up based on tolerability and response.

For both conditions, the calculus often favors the lowest tolerated dose that produces a meaningful effect. Maximum-dose metformin isn't always the goal.

Low-dose metformin for longevity (off-label)

A growing area of off-label interest is "longevity" or "anti-aging" use of low-dose metformin in non-diabetic, otherwise healthy adults. The TAME (Targeting Aging with Metformin) trial, ongoing as of 2026, is studying metformin's effects on age-related conditions in non-diabetic older adults at doses around 1,500 mg/day.

Some popular protocols use 250 to 500 mg/day off-label for proposed longevity benefits. The published evidence for these doses is limited to mechanistic studies, observational data on diabetic populations, and some small randomized trials with mixed results.

A few caveats for low-dose longevity use:

• Recent randomized trials (e.g., the MERIT trial) have suggested that metformin may blunt some training-induced gains in muscle and cardiorespiratory fitness in older adults. The effect appears dose-related and may be relevant at any dose.
• Long-term metformin use, even at low doses, can lower vitamin B12 absorption. Annual B12 testing is reasonable for any extended use.
• Off-label longevity prescribing is a gray area medically and legally. FormBlends doesn't recommend it as a self-directed practice; clinical evaluation and proper bloodwork are basic prerequisites.

For more on related metabolic medications, see our GLP-1 overview.

Comparing low-dose to maximum-dose

A side-by-side reference for what different metformin doses produce:

Dose	A1C reduction (T2D)	Weight loss (non-diabetic)	GI side effect rate
250 mg/day	Not well studied	Probably <1 kg over 6 months	Lowest
500 mg/day	~0.6%	~1 to 2 kg over 6 to 12 months	About 12 to 15%
1,000 mg/day	~1.0%	~2 to 3 kg	About 18%
1,500 mg/day	~1.4%	~2.5 to 3 kg	About 22%
2,000 mg/day	~1.8%	~3 kg	About 25%
2,550 mg/day (max)	~2.0%	~3 kg	About 30%

The dose-response curve for benefit is steeper at lower doses (big gain from 500 to 1,500 mg) and flatter at higher doses (small gain from 1,500 to 2,500 mg). The dose-response curve for side effects is roughly linear across the whole range.

This is why many patients sit comfortably at 1,000 to 1,500 mg/day, capturing most of the benefit while keeping side effects manageable.

When to step up from low dose

Reasons to titrate above 500 mg/day:

• A1C above goal at 4 to 8 weeks. If your fasting glucose or A1C hasn't moved meaningfully at 500 mg, the dose is probably too low to do the job.
• Weight goal not progressing. For non-diabetic weight management, 500 mg often produces sub-threshold weight loss; stepping to 1,000 to 1,500 mg may help.
• PCOS symptoms still pronounced. If 500 mg/day hasn't normalized cycles or reduced androgen markers after 3 to 6 months, escalation is reasonable.
• Tolerability is fine. If you're at 500 mg with no significant GI symptoms, there's little downside to titrating further.

Reasons to stay at 500 mg/day:

• Goal achieved. A1C is at target, weight is moving, PCOS symptoms have improved.
• GI sensitivity. Even 500 mg causes meaningful GI symptoms, and higher doses would be intolerable.
• Other medications doing the heavier lifting. A patient on metformin plus a GLP-1 agonist may not need maximum-dose metformin.

For more on titration logic, see our titration guide.

Side effects at low doses

GI side effects (diarrhea, nausea, abdominal cramping, metallic taste) are dose-dependent. At 500 mg/day, the rate of any GI side effect is around 12 to 15% in clinical trials. At 250 mg/day, the rate is lower but not zero; some patients have GI sensitivity even at very small doses.

Vitamin B12 deficiency is a long-term concern at any dose, including low doses, particularly with use longer than 5 years. The DPP follow-up data showed about 7 to 9% of patients on long-term metformin developed B12 deficiency, with rates increasing with dose and duration.

Lactic acidosis risk is essentially absent at low doses in patients with normal kidney function. The dose-related risk that exists is small even at maximum doses; at 250 to 500 mg/day in a healthy patient, it's a non-issue.

FAQ

What's the lowest dose of metformin you can take? The lowest commercially available tablet is 500 mg immediate-release. By splitting, 250 mg is achievable. Some compounding pharmacies prepare 250 mg capsules on prescription. The label-recommended starting dose is 500 mg once daily.

Can I split a metformin tablet? Yes for immediate-release (IR) tablets, no for extended-release (ER) tablets. Splitting an ER tablet destroys the slow-release coating and changes the absorption profile. IR tablets can be cut with a pill cutter; the halves may not be exactly equal, but the variation is clinically negligible.

Is 500 mg of metformin enough? For some uses, yes. 500 mg/day reduces A1C by about 0.6% in trials, produces modest weight loss in non-diabetic patients, and improves insulin sensitivity in PCOS. For full glycemic control in established type 2 diabetes, 500 mg is usually a starter dose, not a maintenance dose.

What's the lowest effective metformin dose for PCOS? Most PCOS guidelines recommend titrating up to 1,500 to 2,000 mg/day, but 500 to 1,000 mg/day produces measurable effects in many patients. Start at 500 mg/day with food, titrate up over 4 to 6 weeks based on tolerability and response.

Can I take 250 mg of metformin daily for longevity? Some longevity-focused clinicians prescribe 250 to 500 mg/day off-label, but the published evidence for these doses in healthy adults is limited. Recent data suggesting metformin may blunt training-induced fitness gains is worth discussing with your provider.

Why does my doctor want me on 1,500 mg if 500 mg works? The dose-response curve for A1C reduction is steepest between 500 and 1,500 mg/day. Most clinicians push toward this range to capture more of the benefit. If 500 mg is sufficient for your goals (A1C, weight, PCOS), there's no automatic requirement to go higher.

Does 500 mg of metformin cause weight loss? Modestly. Non-diabetic patients on 500 mg/day lose about 1 to 2 kg over 6 to 12 months, less than the 2 to 3 kg seen at higher doses. Weight loss isn't metformin's main mechanism for most patients; it's a secondary effect.

Can I start on 250 mg if I'm sensitive to medications? Yes, with a pill cutter on a 500 mg IR tablet. This is a common protocol for patients with prior GI issues or general medication sensitivity. Hold at 250 mg for 1 to 2 weeks, then double to 500 mg if tolerated.

Is 500 mg metformin safe to take long-term? Yes, in patients with normal kidney function. Long-term safety data spans 20+ years. The main long-term concern is B12 deficiency, which can be monitored with annual B12 levels and corrected with oral or injectable B12 if needed.

Will 500 mg of metformin lower my A1C below 5.7? Probably not on its own, if you're starting in the prediabetic range (5.7 to 6.4%). 500 mg typically reduces A1C by about 0.5 to 0.8%, so a starting A1C of 6.0% might drop to 5.4 to 5.5%. But most prediabetic patients also benefit from lifestyle changes, which compound the metformin effect.

Can I take metformin every other day? Not standard. Metformin's plasma half-life is about 4 to 9 hours, so once-daily dosing is the minimum frequency for sustained effect. Every-other-day dosing would mean substantial gaps in therapeutic exposure. If 500 mg daily is too much, splitting to 250 mg daily is more pharmacologically sound.

Does liquid metformin let me take a smaller dose? Yes. Riomet liquid contains 500 mg per 5 mL, so 1 mL = 100 mg. This lets you measure doses as small as 100 mg, which can be useful for very dose-sensitive patients. Liquid metformin is more expensive and less widely stocked than tablets.

Sources

1. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
2. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (Diabetes Prevention Program). N Engl J Med. 2002;346:393-403.
3. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951-955.
4. Teede HJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33:1602-1618.
5. Aroda VR, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101:1754-1761.
6. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.
7. U.S. Food and Drug Administration. Glucophage (metformin hydrochloride) prescribing information.
8. Garber AJ, et al. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491-497.
9. Konopka AR, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019;18:e12880.
10. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications. Lancet Diabetes Endocrinol. 2015;3:866-875.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Glucophage, Glucophage XR, and Riomet are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.